News Agencies Feed :


November 13, 2019

Sidi Harazem Admits to Knowing About ‘Microbes’ in Mineral Water

Rabat – The Moroccan Federation of Consumer Rights warned citizens of the existence of microbes in some bottled water produced in a recently acquired manufacturing unit.

On November 11, the federation said"...

November 12, 2019

96% of Moroccan Employees Suffer From Stress

Rabat – Around 96% of Moroccan Employees have admitted to suffering from stress related to their work and daily life. Mercer, the world’s largest human resources consulting firm, recently published the results of its study on the perception of work in Morocco.


November 12, 2019

Boehringer Ingelheim and Lilly initiate first ever study to assess empagliflozin in people hospitalised for acute heart failure who have been stabilised

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth Phase III study in the empagliflozin heart failure programme. The study will assess whether in-hospital administration of empagliflozin 10 mg daily improves heart failure outcomes"...

November 11, 2019

Mary Kay Continues Its Commitment to Advance Skin Science Research at the Japanese Society of Investigative Dermatology

As a leader in skincare innovation worldwide, Mary Kay Inc. continued its commitment to advance skin science as a symposium sponsor at the 44th annual meeting of The Japanese Society of Investigative Dermatology (JSID). At the conference held Nov. 8 - 10 in Aomori, Japan, the symposium"...

November 11, 2019

Male infertility is becoming a growing concern for couples looking to start a family

To raise awareness regarding matters surrounding men’s health and in observance of ‘Movember,’ an annual event involving the growing of moustaches all through the month of November, Fakih IVF Fertility Center has a special line-up of services rolled out for all its male"...

November 10, 2019

Moroccan Pension Fund to Buy 5 University Hospital Centers

Rabat – The Moroccan Minister of Economy and Finance, Mohamed Benchaaboun, announced that the Moroccan Pension Fund (CMR) will buy five university hospital centers (CHU). Benchaaboun has not disclosed the hospitals’ names. Benchaaboun made the announcement at a press conference"...

November 10, 2019

Moroccan Parliament Debates Progressive Sugar Tax

Rabat – As Morocco’s 2020 Finance Bill is under review by Parliament, debate has sparked regarding progressive measures to ensure the health of Moroccan citizens.

The internal consumption tax (ICT),"...

November 10, 2019

Morocco Inks Nuclear Medicine Agreement with International Partners

Rabat – The minister of Energy, Hydrocarbons, and the environment Aziz Rabbah signed a Memorandum of Understanding (MoU) with the National Center for Energy and Nuclear Science and Technology (CNSTN), the American Long Island University, France’s Dassault Systemes, and the national"...

November 10, 2019

Phase 3 Trial of NINLAROTM (ixazomib) as First Line Maintenance Therapy Met Primary Endpoint in Multiple Myeloma Patients not treated with Stem Cell Transplantation

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (Takeda) today announced the randomized, Phase 3 TOURMALINE-MM4 study met its primary endpoint of progression free survival (PFS). The trial evaluated the effect of single-agent oral NINLARO™ (ixazomib) as a first line maintenance therapy versus placebo in adult patients diagnosed with multiple myeloma not treated with stem cell transplantation. TOURMALINE-MM4 is the first industry sponsored Phase 3 trial to explore the concept of “switch” maintenance, the use of medicines not included in initial induction therapy, in this setting. NINLARO is currently not approved......

November 8, 2019

New Analyses from the Phase 3 HELP Study™ Open-Label Extension in Hereditary Angioedema Evaluate Efficacy and Safety of TAKHZYRO® (lanadelumab-flyo) Injection During Extended Study Treatment Period

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced new data that further investigates the long-term safety and efficacy of TAKHZYRO® (lanadelumab-flyo) injection in patients with hereditary angioedema (HAE) 12 years of age and older studied in the ongoing Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (OLE). The analyses, being presented at the 2019 American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting in Houston, Texas from November 7-11, showed that TAKHZYRO continued to prevent HAE attacks at a rate similar to that observed......

Stock Market






9 209,87

0,82 %

9 135,23


11 329,76

0,81 %

11 238,86


10 269,41

0,50 %

10 218,62

Found articles: - Pages  
Contact US | Powered by - All Rights Reserved